(NasdaqGM:CRSP), -2026 is poised to be a data- and milestone-rich year across the portfolio- -CASGEVY(R) launch acceleration continues, supporting multi-billion-dollar potential- -Broad pipeline supported by leading gene-editing and siRNA platforms across cardiovascular, autoimmune, oncology and rare diseases- -Starting 2026 with a strong balance sheet with approximately $2 billion in cash, cash equivalents, and marketable securities- […]

The Risk & Insurance Education Alliance proudly announces its role as the first official sponsor of the InsHER Podcast, a groundbreaking series dedicated to celebrating and elevating women shaping the insurance industry. Hosted by Megan Bell, InsHER features inspiring conversations with remarkable women who share their unique stories, insights, and advice, fostering community and promoting

CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones GlobeNewswire January 12, 2026 -2026 is poised to be a data- and milestone-rich year across the portfolio- -CASGEVY(R) launch acceleration continues, supporting multi-billion-dollar potential- -Broad pipeline supported by leading gene-editing and siRNA platforms across cardiovascular, autoimmune, oncology and rare diseases- -Starting 2026 with a strong balance

(NASDAQ:MBRX), – First MIRACLE trial unblinding expected Q1 2026; Global trial now spans nine countries – Investigator-Initiated (IIT) funded pancreatic and brain cancer trials HOUSTON, Jan. 12, 2026 (GLOBE NEWSWIRE) — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and

Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs GlobeNewswire January 12, 2026 – First MIRACLE trial unblinding expected Q1 2026; Global trial now spans nine countries – Investigator-Initiated (IIT) funded pancreatic and brain cancer trials HOUSTON, Jan. 12, 2026 (GLOBE NEWSWIRE) —

MediKarma is the “Intel Inside” of the healthcare economy. Payers and platforms can now license specific AI Agents – longevity, prevention and chronic disease focused – along with the industry's only universal EMR data ingestion engine. MediKarma today announced a defining strategic shift with the launch of its Agentic AI Licensing Program, making it the

(NYSE:BC), METTAWA, Ill., Jan. 12, 2026 (GLOBE NEWSWIRE) — Brunswick Corporation (NYSE: BC) will release its 2025 fourth quarter and full year financial results on Thursday, January 29, 2026 before the market opens by way of an advisory release, notifying the public that the complete and full-text results will be available on the Company's website

Brunswick Corporation Schedules 2025 Fourth Quarter and Full Year Earnings Conference Call GlobeNewswire January 12, 2026 METTAWA, Ill., Jan. 12, 2026 (GLOBE NEWSWIRE) — Brunswick Corporation (NYSE: BC) will release its 2025 fourth quarter and full year financial results on Thursday, January 29, 2026 before the market opens by way of an advisory release, notifying

Full year revenue growth of approximately 94% driven by strong performance in molecular profiling services Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2025. Fourth quarter 2025 preliminary unaudited financial results

Strong Sephience(TM) (sepiapterin) launch continues with unaudited Q4 global revenue of $92.5M – Unaudited 2025 total product and royalty revenue of approximately $823M, exceeding guidance – 2026 product revenue guidance of $700 – 800M, representing 19 – 36% year-over-year growth – Strong cash position of approximately $1.94B as of December 31 – PTC Therapeutics, Inc.